Antigen processing by the proteasome

Nature Reviews Molecular Cell Biology

Volumn 2, Issue 3, 2001, Pages 179-187

  Kloetzel, Peter M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYSTEINE PROTEINASE; MULTIENZYME COMPLEX; PROTEASOME; UBIQUITIN;

ANTIGEN PRESENTATION; CHEMICAL STRUCTURE; CHEMISTRY; IMMUNOLOGY; METABOLISM; REVIEW;

ANTIGEN PRESENTATION; ANTIGENS; CYSTEINE ENDOPEPTIDASES; MODELS, MOLECULAR; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITINS;

EID: 0035290730     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/35056572     Document Type: Review

References (88)

1. Coux, O., Tanaka, K. & Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65, 801-847 (1996). This review gives a good basic introduction to the proteasome system, its components and its different functions.
2. Rock, K. L. et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 27, 761-771 (1994). With the aid of a proteasome-specific inhibitor, this paper describes the first experiments demonstrating that inhibition of proteasome activity impairs antigen presentation.
3. Glickman, M H. et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and elF3. Cell 94, 615-623 (1998).
4. Deveraux, Q., Ustrell, V., Pickart, C. & Rechsteiner, M. A 263 subunit that binds ubiquitin conjugates. J. Biol. Chem. 267, 22369-22377 (1994).
5. Braun, B. C. et al. The base of the proteasome regulatory particle exhibits ATP-dependent chaperone-like activity. Nature Cell Biol. 1, 221-226 (1999). The first demonstration that the base has a chaperone-like function. A model is discussed in which the 19S regulatory particle is responsible for the binding, unfolding and channelling of substrates.
6. Strickland, E., Hakala, K., Thomas, P. J. & DeMartino, G. N. Recognition of misfolded proteins by PA 700, the regulatory subcomplex of the 26S proteasome. J. Biol. Chem. 275, 5565-5572 (2000).
7. Glickman, M. H. et al. Functional analysis of the proteasome regulatory particle. Mol. Biol. Reprod. 26, 21-28 (1999).
8. Groll, M. et al. Structure of the 20S proteasome from yeast at 2.4 Å resolution. Nature 386, 463-471 (1997). The first X-ray structure analysis of a eukaryotic 20S proteasome presents structural evidence that the central gate of the 20S proteasome is closed. The six active sites In the catalytic cavity are defined by co-crystallization with proteasome inhibitors.
9. Löwe, J. et al. Crystal structure of the 20S proteasome from the archaeon T: acidophilum at 3.4 Å resolution. Science 268, 533-539 (1995).
10. Fenteany, G. et al. Inhibition of proteasome activity and subunit specific amino terminal modification of lactacystin. Science 268, 726-731 (1995).
11. Chen, P. & Hochstrasser, M. Autocatalytic subunit processing couples active sites formation in the 20S proteasome to completion of assembly. Cell 86, 961-972 (1996).
12. Schmidtke, G. et al. Analysis of proteasome biogenesis: The maturation of β-subunits is an ordered two step mechanism involving autocatalysis. EMBO J. 15, 6887-6898 (1996).
13. Kisselev, A. F., Akopian, T. N., Woo, K. M. & Goldberg, A. L. The sizes of peptides generated from protein by mammalian 26 and 20S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J. Biol. Chem. 274, 3363-3371 (1999).
14. Schmidtke, G. et al. Inactivation of a defined active site in the mouse 20S proteasome complex enhances inactivation MHC class I antigen presentation of a murine cytomegalovirus protein. J. Exp. Med. 10, 1641-1664 (1998).
15. Rammensee, H. G., Friede, T. & Stevanovic, S. MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178-228 (1995).
16. Madden, D. R. The three dimensional structure of peptide MHC complexes. Annu. Rev. Immunol. 13, 587-622 (1995).
17. Falk, K. et al. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J. Exp. Med. 174, 425-434 (1991).
18. Schwartz, K. et al. The selective proteasome inhibitors lactacystin and expoxmycin can be used to either up- or down-regulate antigen presentation at non-toxic doses. J. Immunol. 164, 6147-6157 (2000).
19. Wheatley, D. N., Grisola, S. & Hernandez-Yago, J. Significance of rapid degradation of newly synthesised proteins in mammalian cells: A working hypothesis. J. Theor. Biol. 98, 283-300 (1982).
20. Schubert, U. et al. Rapid degradation of a large fraction of newly synthesised proteins by proteasomes. Nature 404, 770-774 (2000). Schubert et al. present the first experimental evidence for the DriP (defective ribosomal products) model, which proposes that defective translation products are the main source of MHC class I antigens.
21. Turner, C. C. & Varshavsky, A. Detecting and measuring cotranslational protein degradation. Science 289, 2117-2120 (2000).
22. Reits, E. A. J., Vos, J. C., Grommé, M. & Neffjes, J. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404, 744-748 (2000). In support of the DRiP model, the authors present evidence that TAP peptide transport activity relies on de novo protein synthesis.
23. Kloetzel, P. M., Falkenburg, P. E., Hössl, P. & Glätzer, K. H. The 19S ring-type particles of Drosophila: Cytological and biochemical analysis of their intracellular association and distribution. Exp. Cell Res. 170, 204-213 (1987).
24. Rock, K. & Goldberg, A. L. Degradation of cell proteins and the generation of MHC class I presented peptides. Annu. Rev. Immunol. 17, 737-779 (1999).
25. Nandi, D., Woodwards, E., Ginsburg, D. B. & Monaco, J. J. Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor β-subunits EMBO J. 17, 5363-5375 (1997).
26. Frentzel, S., Pesold-Hurt, B., Seelig, A. & Kloetzel, P. M. 20S proteasomes are assembled via distinct precursor complexes: Processing of LMP2 and LMP7 proproteins takes place in 13-16S preproteasome complexes. J. Mol. Biol. 236, 975-981 (1994).
27. Schmidt, M. et al. Sequence information within the proteasomal prosequence mediates efficient integration of β-subunits into the 20S proteasome complex. J. Mol. Biol. 288, 99-110 (1999).
28. Schmidtke, G. et al. Analysis of mammalian 203 proteasome biogenesis: the maturation of β-subunits is an ordered two step mechanism involving autocatalysis. EMBO J. 15, 6887-6898. (1996).
29. Witt, E. et al. Characterisation of the newly identified human Ump1 homologue POMP and analysis of LMP7 (β5i) incorporation into 20S proteasomes. J. Mol. Biol. 30, 1-9 (2000).
30. Groettrup, M., Standera, S., Stohwasser, R. & Kloetzel, P. M. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc. Natl Acad. Sci. USA 94, 8970-8975 (1996).
31. Griffin, T. A. et al. Immunoproteasome assembly: cooperative incorporation of inferon-γ (IFN-γ) inducible subunits. J. Exp. Med. 187, 97-104 (1998).
32. Schmidt, M. & Kloetzel, P. M. Biogenesis of eukaryotic proteasomes: the complex maturation pathway of a complex enzyme. FASEB J. 11, 1235-1243 (1997).
33. Sijts, A. et al. Structural features of immunoproteasomes determine the efficient generation of a viral CTL epitope. J. Exp. Med. 191, 503-513 (2000). Experimental evidence is presented that the β5i (LMP7) subunit influences the structure of the immunoproteasomes and affects the activity of the two other immunosubunits.
34. Schmidtke, G. et al. Inactivation of a defined active site in the mouse 20S proteasome complexes enhances MHC class I presentation of a murine cytomegalovirus protein. J. Exp. Med. 187, 1641-1646 (1998).
35. Dahlmann, B. et al. Different proteasomes subtypes in a single tissue exhibit different enzymatic properties. J. Mol. Biol. 303, 643-653 (2000).
36. Sijts, A. et al. MHC class I antigen processing of an Adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. J. Immunol. 164, 450-456 (2000). This paper describes the establishment of tetracycline-regulated immunosubunit expression and presents evidence that only minor amounts of immunoproteasomes are required for efficient antigen presentation.
37. van Hall, T. et al. Differential influence on CTL epitope presentation by controlled expression of either proteasome immuno-subunits or PA28. J. Exp. Med. 192, 483-492 (2000).
38. Schwarz, K. et al. Overexpression of the proteasome subunits LMP2, LMP7 and MECL-1 but not PA28α/β enhances the presentation of an immunodominant lymphocyte choriomeningitis virus T cell epitope. J. Immunol. 165, 768-778 (2000).
39. Dubiel, W., Pratt, G., Ferrell, K. & Rechsteiner, M. Purification of a 11S regulator of the multicatalytic proteinase. J. Biol. Chem. 267, 22369-22377 (1992).
40. Ma, C. P., Slaugther, C. A. & DeMartino, G. N. Identification, purification and characterisation of a protein activator (PA28) of the 20S proteasome (macropain). J. Biol. Chem. 267, 10515-10523 (1992).
41. Knowlton, J. R. et al. Structure of the proteasome activator REGα (PA28α). Nature 390, 639-643 (1997).
42. Realini, C. et al. Molecular cloning and expression of a γ-interferon inducible activator of the multicatalytic proteinase. J. Biol. Chem. 269, 20727-20732 (1994).
43. Groettrup, M. et al. A role for the proteasome regulator PA28α in antigen presentation. Nature 381, 166-168 (1996).
44. Schwarz, K. et al. The proteasome regulator PA28α/β can enhance antigen presentation without affecting 20S proteasome subunit composition. Eur. J. Immunol. (in the press).
45. -l- mice. Science 286, 2162-2165 (1999).
46. Dick, T. P. et al. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86, 253-256 (1996).
47. Shimbara, N. et al. Double cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region. Genes Cells 2, 785-800 (1997).
48. Stohwasser, R. et al. Kinetic evidences for facilitation of peptide channelling by the proteasome activator PA28. Eur. J. Biochem. 276, 6221-6239 (2000).
49. Tanahashi, N. et al. Hybrid proteasomes: Induction by interferon-γ and contribution to ATP-dependent proteolysis. J. Biol. Chem. 275, 14336-14345 (2000).
50. Groll, M. et al. A gated channel into the proteasome core particle. Nature Struct. Biol. 7, 1062-1067 (2000). X-ray structure analysis shows that gating is most likely a regulated mechanism and that a single residue within the amino terminus of the α3 subunit is responsible for opening and closing the gate.
51. McGuire, M. J., Mc Cullough, M. L., Croall, D. E. & DeMartino, G. N. The high molecular weight multicatalytic proteinase, macropain, exists in a latent form in human erythrocytes. Biochim. Biophys. Acta 995, 181-186 (1989).
52. Dahlmann, B., Rutschmann, M., Kuehn, L. & Reinauer, H. Activation of the multicatalytic proteinase from skeletal muscle by fatty acid and sodium dodecyl sulphate. Biochem. J. 228, 171-177 (1985).
53. Kuckelkom, U. et al. The effect of heat shock on 20S/26S proteasomes. Biol. Chem. 381, 1017-1024 (2000).
54. Whitby, F. G. et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408, 115-120 (2000). Presents the first co-crystallization of the proteasome activator PA28 with the 20S proteasome and explains how PA28 facilitates the opening of the gate.
55. Thrower, J. S., Hofmann, L., Rechsteiner, M. & Pickart, C. M. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94-102 (2000).
56. Nussbaum, A. K. et al. Cleavage motifs of the yeast proteasome β-subunits deduced from digests of enolase 1. Proc. Natl Acad. Sci. USA 95, 12504-12509 (1998).
57. Wenzel, T., Eckerskorn, C., Lottspeich, F. & Baumeister, W. Existence of a molecular ruler in proteasomes suggestes by analysis of degradation products. FEBS Lett. 349, 205-209 (1994).
58. Lauvau, G. et al. Human transporters associated with antigen processing (TAPs) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells. J. Exp. Med. 190, 1227-1240 (1999).
59. Neisig, A. et al. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I presentable peptides and the effect of flanking sequences. J. Immunol. 154, 1273-1279 (1995).
60. Mo, X. Y. et al. Distinct proteolytic processes generate the C and N-termini of the MHC class I-binding peptides. J. Immunol. 163, 5851-5859 (1999).
61. Niedermann, G. et al. Contribution of proteasome mediated proteolysis to the hierarchy of epitopes presented by major histocompatibiliy complex class I molecules. Immunity 2, 289-299 (1995).
62. Del Val, M. et al. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighbouring residues in proteins. Cell 66, 1145-1153 (1991). This paper presents, for the first time, experiments showing that the efficiency of antigen processing depends on the sequence environment of the epitope.
63. Theobald, M. et al. A mutational hotspot in p53 protects cells from lysis by CTL specific for a flanking epitope. J. Exp. Med. 11, 1017-1020 (1998).
64. Beekman, N. J. et al. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J. Immunol. 164, 1898-1905 (2000).
65. Ossendorp, F. et al. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 5, 115-124 (1996).
66. Holzhütter, H. G., Frömmel, C. & Kloetzel, P. M. A theoretical approach towards the identification of cleavage determining amino acid motifs of the 20S proteasome. J. Mol. Biol. 286, 1251-1265 (1999). The first mathematical model that permits the identification of proteasomal cleavage sites in a substrate protein.
67. Shimbara, N. et al. Contribution of proline residue for efficient production of MHC class I ligands by proteasomes. J. Biol. Chem. 273, 23062-23071 (1998).
68. Kraft, R. et al. Influence of single amino acid exchanges in epitope generation by 20S proteasomes. J. Protein Chem. 17, 547-548 (1998).
69. Beninga, J., Rock, K. L. & Goldberg, A. L. Interferon-γ can stimulate post-proteasomal trimming of the N-terminus of an antigenic peptide by inducing leucine aminopeptidase. J. Biol. Chem. 273, 18734-18742 (1998).
70. Kuttler, C. et al. An algorithm for the prediction of proteasome cleavage. J. Mol. Biol. 5, 298, 417-429 (2000).
71. Holzhütter, H.-G. & Kloetzel, P.-M. A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. Biophys. J. 79, 1196-1205 (2000).
72. Rammensee, H. G. et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 313-316 (1999).
73. Yewdell, J. W. & Bennik, J. R. Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu. Rev. Cell Dev. Biol. 15, 579-606 (1999).
74. Rousset, R., Desbois, C., Bantignies, F. & Jalinot, P. Effects of the NF-kB1/105 processing of the interaction between HTLV-1 transactivator Tax and the proteasome. Nature 381, 328-331 (1996).
75. Fischer, M., Runkel, L. & Schaller, H. HBx protein of hepatitis B virus interacts with the C-terminal portion of a novel human proteasome a-subunit. Virus Genes 10, 99-102 (1995).
76. Huang, J., Kwong, J., Sun, E. C. & Liasng, T. J. Proteasome complex as a potential cellular target for hepatitis B virus X protein. J. Virol. 70, 5582-5591 (1996).
77. Rossi, F. et al. HsN3 proteasomal subunits as a target for human immunodeficiency virus type 1 Nef protein. Virology 237, 33-45 (1997).
78. Turnell, A. S. et al. Regulation of 26S proteasome by adenovirus. EMBO J. 19, 4759-4773 (2000).
79. Seeger, M., Ferrell, K., Frank, R. & Dubiel, W. HIV-tat inhibits the 20S proteasome and its 11S regulator-mediated activation. J. Biol. Chem. 272, 8145-8148 (1997).
80. Young, P. et al. Characterisation of two polyubiquitin binding sites in the 26S protease subunit 5a. J. Biol. Chem. 273, 5461-5467 (1998).
81. Elliot, T. Transporter associated with antigen processing. Adv. Immunol. 65, 47-109 (1997).
82. Momburg, F. & Hämmerling, G. J. Generation of TAP mediated trasnport of peptides for major histocampatibility complex class I molecules. Adv. Immunol. 68, 191-256 (1998).
83. Pamer, E. & Cresswell, P. Mechanism of MHC class I restricted antigen processing. Annu. Rev. Immunol. 16, 323-358 (1998).
84. Hughes, E. A. & Cresswell, P. The thiooxidoreductase ERp57 is a component of the MHC class I peptide loading complex. Curr. Biol. 8, 709-712 (1998).
85. Morrice, N. A. & Powis, S. J. A role for the thiol-dependent reductase ERp57 in the assembly of MHC class I molecules. Curr. Biol. 8, 713-716 (1998).
86. Van Kaer, L. et al. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1, 533-541 (1994).
87. Fehling, H. J. et al. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 265, 1234-1237 (1994).
88. Morel, S. et al. Processing of some antigens by standard proteasome but not by the immunoproteasome result in poor presentation by dendritic cells. Immunity 12, 101-117 (2000).